ImageneBio logo
ImageneBio
IMA | NASDAQ
Chart Builder DCF Calculator
$3.20
-$0.27 (-7.78%)
At close: Nov 16, 2026, 4:00 PM ET
$3.20
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET

ImageneBio Company Profile

Company profile explained

Company Profile

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Key Executives

Name Position
Kristin Yarema CEO & Director
Kurinji Pandiyan Chief Strategy & Operations Officer
Matt Robbins General Counsel
Renuka Sivendran Chief Technical Officer
Yanina Grant-Huerta CFO, Principal Financial Officer & Principal Accounting Officer

Latest SEC Filings

Date Type Title
Aug 17, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 EFFECT Filing
Aug 11, 2026 EFFECT Filing
Aug 06, 2026 EFFECT Filing
Aug 05, 2026 S-8 Filing
Aug 05, 2026 S-3 Filing
Aug 05, 2026 POS AM Filing
Aug 05, 2026 424B3 Filing
View All SEC Filings ➞
ImageneBio
ImageneBio logo
Country United States
IPO Date Feb 27, 1998
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Kristin Yarema

Contact Details

12526 High Bluff Drive, Suite 345, San Diego, CA 92130 San Diego, California 92130 United States

Stock Details

Ticker Symbol IMA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001835579
CUSIP Number 45175G207
ISIN Number US45175G2075
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.